Stock listing
OTC:BCLI Brainstorm Cell Therapeutics Inc. Stock
Follow Brainstorm Cell Therapeutics Inc. into a list and get an email when it puts out news.
Share price · OTC:BCLI
$0.753 USD -0.099 (-11.6%)
Close on Nov 20, 2026
- Day range
- $0.753 – $0.810 USDNov 20, 2026
- Volume
- 7,775 sharesNov 20, 2026
- Market cap
- $8.31M USDAt the close on Nov 20, 2026 · price × 11.03M shares outstanding
- 52-week range
- $0.460 – $1.690 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $15,846 USDMedian day 11,483 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OTC:BCLI · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.753 | -0.099 | -11.6% | $0.810 | $0.810 | $0.753 | 7,775 | |
| $0.852 | -0.029 | -3.3% | $0.840 | $0.852 | $0.840 | 2,504 | |
| $0.881 | -0.019 | -2.1% | $0.960 | $0.998 | $0.881 | 62,843 | |
| $0.900 | -0.090 | -9.1% | $0.950 | $0.950 | $0.891 | 3,850 | |
| $0.990 | 0.000 | 0.0% | $0.990 | $1.000 | $0.970 | 36,289 | |
| $0.990 | +0.035 | +3.7% | $0.990 | $1.020 | $0.950 | 39,634 | |
| $0.955 | -0.018 | -1.8% | $0.973 | $0.990 | $0.876 | 11,483 | |
| $0.973 | +0.024 | +2.5% | $0.965 | $0.989 | $0.864 | 15,609 | |
| $0.949 | +0.049 | +5.4% | $0.830 | $0.949 | $0.830 | 19,120 | |
| $0.900 | +0.040 | +4.7% | $0.932 | $0.932 | $0.802 | 4,045 | |
| $0.860 | +0.034 | +4.1% | $0.811 | $0.860 | $0.700 | 14,703 | |
| $0.826 | 0.000 | 0.0% | $0.826 | $0.826 | $0.811 | 1,878 | |
| $0.826 | +0.000 | 0.0% | $0.850 | $0.850 | $0.826 | 10,252 | |
| $0.826 | -0.034 | -4.0% | $0.828 | $0.828 | $0.811 | 367 | |
| $0.860 | -0.049 | -5.3% | $0.870 | $0.943 | $0.856 | 3,476 | |
| $0.909 | +0.109 | +13.6% | $0.800 | $0.943 | $0.800 | 67,566 | |
| $0.800 | 0.000 | 0.0% | $0.753 | $0.800 | $0.753 | 4,721 | |
| $0.800 | +0.028 | +3.6% | $0.800 | $0.800 | $0.753 | 2,566 | |
| $0.772 | -0.048 | -5.8% | $0.788 | $0.803 | $0.765 | 6,538 | |
| $0.820 | +0.040 | +5.1% | $0.800 | $0.830 | $0.750 | 28,900 | |
| $0.780 | +0.010 | +1.3% | $0.750 | $0.830 | $0.750 | 9,500 | |
| $0.770 | -0.030 | -3.8% | $0.750 | $0.830 | $0.750 | 3,200 | |
| $0.800 | +0.030 | +3.9% | $0.810 | $0.830 | $0.750 | 18,100 | |
| $0.770 | -0.010 | -1.3% | $0.830 | $0.830 | $0.770 | 6,800 | |
| $0.780 | -0.020 | -2.5% | $0.840 | $0.840 | $0.780 | 7,400 | |
| $0.800 | -0.040 | -4.8% | $0.840 | $0.840 | $0.800 | 2,500 | |
| $0.840 | +0.010 | +1.2% | $0.770 | $0.840 | $0.770 | 21,100 | |
| $0.830 | -0.020 | -2.4% | $0.850 | $0.850 | $0.770 | 24,400 | |
| $0.850 | -0.100 | -10.5% | $0.870 | $0.940 | $0.850 | 12,800 | |
| $0.950 | +0.040 | +4.4% | $0.930 | $0.960 | $0.880 | 16,400 | |
| $0.910 | +0.010 | +1.1% | $0.890 | $0.960 | $0.890 | 700 | |
| $0.900 | -0.130 | -12.6% | $0.960 | $0.960 | $0.900 | 6,300 | |
| $1.030 | -0.020 | -1.9% | $0.950 | $1.030 | $0.950 | 900 | |
| $1.050 | +0.120 | +12.9% | $1.000 | $1.050 | $0.920 | 11,700 | |
| $0.930 | -0.070 | -7.0% | $0.950 | $1.030 | $0.900 | 16,600 | |
| $1.000 | +0.050 | +5.3% | $0.940 | $1.080 | $0.920 | 17,400 | |
| $0.950 | +0.030 | +3.3% | $0.880 | $0.950 | $0.880 | 7,700 | |
| $0.920 | -0.020 | -2.1% | $0.920 | $0.920 | $0.920 | 900 | |
| $0.940 | -0.030 | -3.1% | $0.910 | $0.970 | $0.910 | 1,400 | |
| $0.970 | +0.020 | +2.1% | $0.980 | $0.980 | $0.960 | 20,600 | |
| $0.950 | +0.080 | +9.2% | $0.990 | $1.080 | $0.920 | 19,000 | |
| $0.870 | -0.070 | -7.4% | $0.830 | $0.990 | $0.830 | 1,700 | |
| $0.940 | +0.070 | +8.0% | $0.870 | $0.940 | $0.870 | 2,200 | |
| $0.870 | -0.030 | -3.3% | $0.870 | $0.900 | $0.850 | 17,700 | |
| $0.900 | -0.080 | -8.2% | $1.000 | $1.000 | $0.850 | 26,800 | |
| $0.980 | 0.000 | 0.0% | $0.930 | $1.030 | $0.920 | 8,400 | |
| $0.980 | -0.060 | -5.8% | $0.970 | $1.010 | $0.920 | 32,900 | |
| $1.040 | -0.020 | -1.9% | $1.060 | $1.080 | $0.960 | 7,600 | |
| $1.060 | -0.020 | -1.9% | $1.060 | $1.070 | $1.060 | 1,800 | |
| $1.080 | +0.050 | +4.9% | $1.060 | $1.080 | $1.020 | 42,900 | |
| $1.030 | +0.030 | +3.0% | $1.000 | $1.070 | $1.000 | 17,900 | |
| $1.000 | +0.010 | +1.0% | $0.980 | $1.060 | $0.980 | 6,900 | |
| $0.990 | -0.060 | -5.7% | $1.000 | $1.050 | $0.980 | 6,900 | |
| $1.050 | -0.020 | -1.9% | $1.060 | $1.060 | $1.030 | 7,200 | |
| $1.070 | -0.180 | -14.4% | $1.260 | $1.340 | $1.050 | 42,391 | |
| $1.250 | +0.080 | +6.8% | $1.180 | $1.300 | $1.130 | 19,600 | |
| $1.170 | +0.100 | +9.3% | $1.080 | $1.190 | $1.030 | 3,700 | |
| $1.070 | -0.050 | -4.5% | $1.070 | $1.090 | $0.980 | 23,400 | |
| $1.120 | -0.040 | -3.4% | $1.150 | $1.190 | $1.070 | 3,600 | |
| $1.160 | -0.040 | -3.3% | $1.200 | $1.220 | $1.110 | 22,100 | |
| $1.200 | +0.200 | +20.0% | $0.990 | $1.270 | $0.990 | 48,300 | |
| $1.000 | 0.000 | 0.0% | $1.000 | $1.000 | $0.990 | 16,000 | |
| $1.000 | +0.020 | +2.0% | $0.980 | $1.030 | $0.900 | 23,900 | |
| $0.980 | -0.080 | -7.5% | $1.110 | $1.130 | $0.900 | 51,500 | |
| $1.060 | -0.160 | -13.1% | $1.210 | $1.230 | $1.000 | 56,500 |
Splits
3 splits since 2003 · OTC:BCLI · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-15 | Consolidation | |
| 1-for-15 | Consolidation | |
| 2-for-1 | Split |
- Ticker
- OTC:BCLI
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- OTC
- Currency
- USD
What changed lately
Latest news release · Nov 20, 2026
Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Matters
Latest news
BrainStorm Cell Therapeutics Announces Third Quarter 2026 Financial Results and Provides Corporate Update
Nov 16, 2026
Closed $0.881 (-2.1%) on Nov 17, 2026
Brainstorm Cell Therapeutics Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 2 in the last 12 months · 2 in all · newest Nov 20, 2026 · oldest 2026
- Calls
- 19 calls with a replay · 19 with a transcript · latest Aug 14, 2025
- Decks
- 29 decks · latest May 8, 2025
Valuation
Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $10.08M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 0.40
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Brainstorm Cell Therapeutics Inc. · OTC:BCLI | US$8.31M | US$10.08M | n/a | n/a | n/a | n/a | n/a | n/a | 0.40 |
| BioVie Inc. · NASDAQ:BIVI | US$8.58M | US$1.10M | n/a | n/a | n/a | 1.3× | n/a | 0.0× | 1.84 |
| Vyome Holdings, Inc. · NASDAQ:HIND | US$8.42M | US$1.82M | n/a | 11.9× | n/a | 1.3× | n/a | 0.1× | 1.34 |
| CRISM Therapeutics Corporation · LSE:CRTX | US$8.34M | US$5.37M | n/a | 17.8× | n/a | 2.5× | −823.8% | 0.0× | n/a |
| Quantum Biopharma Ltd. Subordinate Voting Shares Class B · NASDAQ:QNTM | US$8.29M | −US$3.20M | n/a | n/a | n/a | 0.7× | n/a | 0.1× | 1.05 |
| Moleculin Biotech, Inc. · NASDAQ:MBRX | US$8.22M | US$1.04M | n/a | n/a | n/a | 0.6× | n/a | 0.0× | 0.42 |
| IN8bio, Inc. · NASDAQ:INAB | US$8.19M | −US$3.03M | n/a | n/a | n/a | 0.6× | n/a | 0.2× | 1.25 |
| Intensity Therapeutics, Inc. · NASDAQ:INTS | US$8.19M | −US$220,086 | n/a | n/a | n/a | 1.1× | n/a | 0.0× | 1.30 |
| Palatin Technologies, Inc. · AMEX:PTN | US$8.16M | US$4.58M | n/a | 12.7× | n/a | 4.0× | n/a | 0.1× | 0.61 |
| Dare Bioscience, Inc. · NASDAQ:DARE | US$8.01M | −US$2.65M | n/a | −1.9× | n/a | 3.4× | −749.8% | 0.4× | 1.34 |
| Cellectar Biosciences, Inc. · NASDAQ:CLRB | US$8.00M | −US$15.05M | n/a | n/a | n/a | 0.4× | n/a | 0.1× | 1.71 |
| Median of the others | US$8.20M | US$408,090 | 12.3× | 1.2× | −786.8% | 0.1× | 1.30 |
Forecasts
1 buy · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 17.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.91 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Chaim Lebovits | President, Chief Executive Officer |
| Alla Patlis | Interim Chief Financial Officer |
| Haro Hartounian | Executive Vice President, Chief Operating Officer |
| Mary Kay Turner | Senior Vice President, Patient Advocacy and Government Affairs |
| Netta Blondheim-Shraga | Senior Vice President, Research and Development |
| Yossef Levy | Vice President, Cell Production |
| Peter J. Pitts | Executive Chairman |
Board
| Director | Role |
|---|---|
| Peter J. Pitts | Executive Chairman |
| Anthony Polverino | Director |
| Irit Arbel | Director |
| Menghis Bairu | Director |
| Nir Naor | Director |
| Stacy Lindborg | Director |
| Uri Yablonka | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Brainstorm Cell Therapeutics (OTC:BCLI) Q2 2025 Earnings Call | Thu, Aug 14, 2025 · 8:30 AM ET | Replay |
| Brainstorm Cell Therapeutics (OTC:BCLI) Q1 2025 Earnings Call | Mon, May 19, 2025 · 8:30 AM ET | Replay |
| Brainstorm Cell Therapeutics (OTC:BCLI) Q4 2024 Earnings Call | Mon, Mar 31, 2025 · 8:30 AM ET | Replay |
| Brainstorm Cell Therapeutics (OTC:BCLI) Q2 2024 Earnings Call | Wed, Aug 14, 2024 · 8:30 AM ET | Replay |
| Brainstorm Cell Therapeutics (OTC:BCLI) Q3 2023 Earnings Call | Tue, Nov 14, 2023 · 8:30 AM ET | Replay |
| Brainstorm Cell Therapeutics (OTC:BCLI) Q2 2023 Earnings Call | Mon, Aug 14, 2023 · 8:00 AM ET | Replay |
| Brainstorm Cell Therapeutics (OTC:BCLI) Q1 2023 Earnings Call | Mon, May 15, 2023 · 8:00 AM ET | Replay |
| Brainstorm Cell Therapeutics (OTC:BCLI) Q4 2022 Earnings Call | Thu, Mar 30, 2023 · 8:00 AM ET | Replay |
| Brainstorm Cell Therapeutics (OTC:BCLI) Q3 2022 Earnings Call | Mon, Nov 14, 2022 · 8:00 AM ET | Replay |
| Brainstorm Cell Therapeutics (OTC:BCLI) Q2 2022 Earnings Call | Mon, Aug 15, 2022 · 8:00 AM ET | Replay |
All 19 calls
| Call | When | Status |
|---|---|---|
| Brainstorm Cell Therapeutics (OTC:BCLI) Q1 2022 Earnings Call | Mon, May 16, 2022 · 8:00 AM ET | Replay |
| Brainstorm Cell Therapeutics (OTC:BCLI) Q4 2021 Earnings Call | Mon, Mar 28, 2022 · 8:00 AM ET | Replay |
| Brainstorm Cell Therapeutics (OTC:BCLI) Q3 2021 Earnings Call | Mon, Nov 15, 2021 · 8:00 AM ET | Replay |
| Brainstorm Cell Therapeutics (OTC:BCLI) Q2 2021 Earnings Call | Wed, Aug 04, 2021 · 8:00 AM ET | Replay |
| Brainstorm Cell Therapeutics (OTC:BCLI) Q1 2021 Earnings Call | Sun, Apr 25, 2021 · 8:00 AM ET | Replay |
| Brainstorm Cell Therapeutics (OTC:BCLI) Q4 2020 Earnings Call | Wed, Feb 03, 2021 · 8:00 AM ET | Replay |
| Brainstorm Cell Therapeutics (OTC:BCLI) Q3 2020 Earnings Call | Thu, Oct 15, 2020 · 8:00 AM ET | Replay |
| Brainstorm Cell Therapeutics (OTC:BCLI) Q2 2020 Earnings Call | Wed, Aug 05, 2020 · 8:00 AM ET | Replay |
| Brainstorm Cell Therapeutics (OTC:BCLI) Q1 2020 Earnings Call | Thu, May 07, 2020 · 8:00 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 17, 2026 | −5.3% |
| Q2 2026 | Aug 17, 2026 | +42.4% |
| Q1 2026 | May 15, 2026 · After close | 0.0% |
| Q3 2025 | Nov 14, 2025 · After close | +11.5% |
| Q2 2025 | Aug 14, 2025 · Before open | −9.1% |
| Q1 2025 | May 15, 2025 · After close | +13.8% |
| Q4 2024 | Mar 31, 2025 · Before open | +5.9% |
| Q3 2024 | Nov 14, 2024 · After close | +7.1% |
| Q2 2024 | Aug 14, 2024 · Before open | −3.1% |
| Q1 2024 | Apr 1, 2024 · Before open | +32.1% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q3 2023 | Nov 14, 2023 · Before open | 0.0% |
| Q2 2023 | Aug 14, 2023 · Before open | +3.1% |
| Q1 2023 | May 15, 2023 · Before open | 0.0% |
| Q4 2022 | Mar 30, 2023 · Before open | +2.5% |
| Q3 2022 | Nov 14, 2022 · Before open | +7.9% |
| Q2 2022 | Aug 15, 2022 · Before open | −1.4% |
| Q1 2022 | May 16, 2022 · Before open | +4.8% |
| Q4 2021 | Mar 28, 2022 · Before open | −4.4% |
| Quarter to Sep 30, 2021 | Nov 15, 2021 · Before open | +2.4% |
| Quarter to Jun 30, 2021 | Aug 5, 2021 · Before open | +4.5% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (May 2025) | Technical | 8 slides | May 8, 2025 |
| Investor Presentation (October 2024) | Investor deck | 29 slides | October 2024 |
| Investor Presentation (2024) | Investor deck | 29 slides | 2024 |
| Technical Presentation (November 2023) | Technical | 14 slides | Nov 17, 2023 |
| 13th Annual California ALS Research Summit 2023 | Conference | 18 slides | Jan 20, 2023 |
| Biotech Showcase 2023 | Conference | 17 slides | January 2023 |
| ALS ONE, Industry Presentations (October 2022) | Conference | 15 slides | Oct 7, 2022 |
| 32nd International Symposia on ALS/MND 2021 | Conference | 19 slides | December 2021 |
| 2021 ALS One Research Symposium | Conference | 15 slides | Nov 30, 2021 |
| 37th Congress of ECTRIMS 2021 | Conference | 14 slides | October 2021 |
All 29 decks
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 703.0K | 849.0K | 0 | 0 | 0 | 0 | -366.0K | 0 | 0 | 0 |
| Cost of revenue | 240.0K | 265.0K | 285.0K | 260.0K | 219.0K | 366.0K | 110.0K | 85.0K | 77.0K | |
| Gross profit | -240.0K | -265.0K | -285.0K | -260.0K | -219.0K | -732.0K | -110.0K | -85.0K | -77.0K | |
| Research and development | 4.17M | 4.65M | 10.7M | 14.0M | 15.2M | 22.3M | 17.2M | 8.29M | 977.0K | 2.25M |
| Selling, general and administrative | 5.78M | 7.04M | 10.7M | 10.9M | 9.30M | 9.36M | 5.80M | 5.77M | 4.02M | 2.83M |
| Operating income | -9.95M | -11.7M | -21.4M | -24.8M | -24.5M | -31.7M | -23.0M | -14.1M | -5.00M | -5.08M |
| Depreciation and amortization | 199.0K | 240.0K | 265.0K | 285.0K | 260.0K | 219.0K | 164.0K | 110.0K | 85.0K | 77.0K |
| EBITDA | -9.75M | -11.5M | -21.2M | -24.5M | -24.3M | -31.5M | -22.8M | -14.0M | -4.91M | -5.01M |
| Interest expense | 77.0K | 545.0K | 82.0K | 127.0K | 252.0K | 115.0K | 47.0K | 101.0K | ||
| Income before tax | -10.3M | -11.6M | -17.2M | -24.3M | -24.5M | -31.8M | -23.3M | -13.9M | -4.95M | -4.98M |
| Income tax | 11.6M | -545.0K | -82.0K | 127.0K | 252.0K | -115.0K | 0 | 0 | ||
| Net income | -10.3M | -11.6M | -17.2M | -24.3M | -24.5M | -31.8M | -23.3M | -13.9M | -4.95M | -4.98M |
| Earnings per share, basic | -1.11 | -2.31 | -6.00 | -0.66 | -0.68 | -1.07 | -1.06 | -0.70 | -0.26 | -0.27 |
| Earnings per share, diluted | -1.11 | -2.31 | -6.00 | -0.66 | -0.68 | -1.07 | -1.06 | -0.70 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 29.0K | 187.0K | 1.30M | 772.0K | 18.9M | 37.8M | 536.0K | 942.0K | 2.48M | 547.0K |
| Short-term investments | 0 | 2.21M | 3.24M | 4.11M | 33.0K | 6.12M | 5.27M | 9.44M | ||
| Receivables | 86.0K | 63.0K | 51.0K | 91.0K | 86.0K | 304.0K | 2.36M | 2.01M | 672.0K | 306.0K |
| Inventory | -51.0K | 0 | 0 | |||||||
| Current assets | 307.0K | 385.0K | 1.90M | 3.11M | 23.3M | 43.2M | 3.36M | 10.3M | 9.62M | 10.4M |
| Property, plant and equipment | 235.0K | 434.0K | 686.0K | 933.0K | 1.19M | 1.12M | 960.0K | 651.0K | 392.0K | 297.0K |
| Goodwill | 0 | 0 | ||||||||
| Total assets | 1.02M | 1.83M | 4.21M | 8.45M | 29.3M | 51.3M | 6.53M | 11.2M | 11.4M | 10.8M |
| Accounts payable | 7.07M | 6.08M | 4.95M | 6.22M | 3.70M | 5.42M | 14.7M | 4.55M | 1.42M | 345.0K |
| Current liabilities | 11.0M | 8.98M | 7.80M | 8.80M | 6.32M | 11.2M | 17.7M | 6.21M | 5.54M | 864.0K |
| Long-term debt | 0 | 0 | ||||||||
| Total debt | 208.0K | 720.0K | 1.27M | 4.09M | 5.08M | 7.22M | 2.37M | |||
| Total liabilities | 11.0M | 9.60M | 9.07M | 11.5M | 9.94M | 15.8M | 18.8M | 6.21M | 5.54M | 864.0K |
| Shareholders' equity | -9.98M | -7.76M | -4.86M | -3.02M | 19.3M | 35.5M | -12.2M | 5.02M | 5.88M | 9.90M |
| Shares outstanding | 11.0M | 6.14M | 4.03M | 36.7M | 36.4M | 35.2M | 23.2M | 20.8M | 19.0M | 18.7M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -6.97M | -9.09M | -20.5M | -19.3M | -26.3M | -35.2M | -11.2M | -12.4M | -2.36M | -5.86M |
| Capital spending | 0 | 0 | -18.0K | -29.0K | -330.0K | -378.0K | -473.0K | -369.0K | -180.0K | -103.0K |
| Free cash flow | -6.97M | -9.09M | -20.5M | -19.3M | -26.6M | -35.6M | -11.7M | -12.8M | -2.54M | -5.96M |
| Cash from investing | 12.0K | 2.19M | 998.0K | 323.0K | -4.45M | 5.62M | -1.22M | 3.99M | 5.98M | |
| Cash from financing | 6.88M | 7.97M | 19.0M | 238.0K | 6.97M | 76.9M | 5.22M | 12.1M | 314.0K | 0 |
| Dividends paid | 0 | 0 | ||||||||
| Share buybacks | 5.00K | -116.0K | 3.16M | 12.1M | 314.0K | 0 | ||||
| Change in cash | -95.0K | -1.11M | 713.0K | -18.1M | -19.0M | 37.3M | -406.0K | -1.54M | 1.94M | 119.0K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 20, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Nov 16, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 16, 2026 | Results | SEC |
| 10-Q · Quarterly report | Aug 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2026 | Results | SEC |
| 8-K · Current report | Jul 30, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jul 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 28, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 3, 2026 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Jun 3, 2026 | Other filings | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| CORRESP · Letter to the SEC | Jun 1, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 8-K · Current report | May 28, 2026 | Management or board change | SEC |
| UPLOAD · Letter from the SEC | May 27, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | May 20, 2026 | Offer document | SEC |
| S-1 · Registration statement | May 20, 2026 | Offer document | SEC |
| 8-K · Current report | May 15, 2026 | Results | SEC |
| 10-Q · Quarterly report | May 15, 2026 | Quarterly report | SEC |
| 10-K · Annual report | Mar 31, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 31, 2026 | Results | SEC |
| 8-K · Current report | Feb 27, 2026 | Material contract | SEC |
| 8-K · Current report | Feb 13, 2026 | Material contract | SEC |
| 8-K · Current report | Jan 9, 2026 | Material contract | SEC |
| 10-Q · Quarterly report | Nov 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2025 | Results | SEC |
| 8-K · Current report | Nov 6, 2025 | Material contract | SEC |
| 25-NSE | Oct 9, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2025 | Results | SEC |
| RW · Request to withdraw a registration | Jul 22, 2025 | Other filings | SEC |
| 8-K · Current report | Jul 17, 2025 | Current report | SEC |
| S-8 · Registration statement for employee plans | Jul 3, 2025 | Offer document | SEC |
| S-3 · Registration statement | Jun 25, 2025 | Offer document | SEC |
| 8-K · Current report | Jun 25, 2025 | Management or board change | SEC |
| 8-K · Current report | Jun 16, 2025 | Current report | SEC |
| 8-K · Current report | May 19, 2025 | Current report | SEC |
| ARS · Annual report to shareholders | May 16, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | May 16, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | May 16, 2025 | Meeting notice | SEC |
| 10-Q · Quarterly report | May 15, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 15, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2025 | Big-stake notice | SEC |
| PRE 14A · Preliminary proxy statement | May 6, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 21, 2025 | Current report | SEC |
| 10-K · Annual report | Mar 31, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 31, 2025 | Results | SEC |
| 8-K · Current report | Mar 31, 2025 | Material contract | SEC |
| 8-K · Current report | Mar 27, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jan 21, 2025 | Current report | SEC |
| 8-K · Current report | Jan 15, 2025 | Current report | SEC |
| 4 · Change in ownership | Jan 7, 2025 | Insider trade | SEC |
| 3/A · Initial statement of ownership, amended | Jan 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2024 | Results | SEC |
| SC 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 13, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Oct 30, 2024 | Current report | SEC |
| 4 · Change in ownership | Oct 2, 2024 | Insider trade | SEC |
| 8-K · Current report | Oct 1, 2024 | Current report | SEC |
| 8-K · Current report | Oct 1, 2024 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Sep 30, 2024 | Other filings | SEC |
| 8-K · Current report | Sep 26, 2024 | Current report | SEC |
| CORRESP · Letter to the SEC | Sep 26, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 24, 2024 | Other filings | SEC |
| S-3/A · Registration statement, amended | Sep 24, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Sep 20, 2024 | Other filings | SEC |
| S-3 · Registration statement | Sep 17, 2024 | Offer document | SEC |
| 8-K · Current report | Sep 16, 2024 | Management or board change | SEC |
| EFFECT · Notice that a registration is effective | Sep 9, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 4, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Sep 3, 2024 | Other filings | SEC |
| S-3 · Registration statement | Aug 28, 2024 | Offer document | SEC |
| ARS · Annual report to shareholders | Aug 16, 2024 | Annual report | SEC |
| DEF 14A · Proxy statement | Aug 16, 2024 | Meeting notice | SEC |
| 10-Q · Quarterly report | Aug 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2024 | Results | SEC |
| PRER14A | Aug 6, 2024 | Other filings | SEC |
| PRE 14A · Preliminary proxy statement | Aug 5, 2024 | Meeting notice | SEC |
| 4/A · Change in ownership, amended | Jul 31, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jul 31, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jul 31, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jul 31, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jul 31, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jul 31, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jul 31, 2024 | Insider trade | SEC |
| 8-K · Current report | Jul 30, 2024 | Current report | SEC |
| 4 · Change in ownership | Jul 24, 2024 | Insider trade | SEC |
| 8-K · Current report | Jul 19, 2024 | Current report | SEC |
| 424B5 · Prospectus | Jun 28, 2024 | Offer document | SEC |
| 8-K · Current report | Jun 28, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Jun 27, 2024 | Offer document | SEC |
| 8-K · Current report | Jun 26, 2024 | Current report | SEC |
| 4 · Change in ownership | Jun 25, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 25, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 20, 2024 | Management or board change | SEC |
| 8-K · Current report | Jun 4, 2024 | Current report | SEC |
| 4 · Change in ownership | Jun 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | May 14, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | May 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 7, 2024 | Insider trade | SEC |
| 8-K · Current report | May 3, 2024 | Current report | SEC |
| 4 · Change in ownership | Apr 25, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 19, 2024 | Insider trade | SEC |
| 8-K · Current report | Apr 16, 2024 | Management or board change | SEC |
| 8-K · Current report | Apr 11, 2024 | Current report | SEC |
| 8-K · Current report | Apr 9, 2024 | Current report | SEC |
| 424B5 · Prospectus | Apr 2, 2024 | Offer document | SEC |
| 8-K · Current report | Apr 2, 2024 | Material contract | SEC |
| 10-K · Annual report | Apr 1, 2024 | Annual report | SEC |
| 8-K · Current report | Apr 1, 2024 | Results | SEC |
| 4 · Change in ownership | Mar 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 13, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 12, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Dec 20, 2023 | Meeting outcome | SEC |
| DEFA14A · Additional proxy material | Nov 22, 2023 | Meeting notice | SEC |
| 8-K · Current report | Nov 22, 2023 | Current report | SEC |
| 10-Q · Quarterly report | Nov 14, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2023 | Results | SEC |
| 8-K · Current report | Nov 9, 2023 | Current report | SEC |
| DEF 14A · Proxy statement | Nov 8, 2023 | Meeting notice | SEC |
| 8-K · Current report | Nov 3, 2023 | Current report | SEC |
| 8-K · Current report | Oct 24, 2023 | Management or board change | SEC |
| 4 · Change in ownership | Sep 5, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 14, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2023 | Results | SEC |
| 4 · Change in ownership | Aug 7, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 4, 2023 | Insider trade | SEC |
| 8-K · Current report | Jul 19, 2023 | Material contract | SEC |
| 424B5 · Prospectus | Jul 19, 2023 | Offer document | SEC |
| 4 · Change in ownership | Jun 21, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 21, 2023 | Insider trade | SEC |
| 8-K · Current report | Jun 20, 2023 | Management or board change | SEC |
| 8-K · Current report | Jun 6, 2023 | Current report | SEC |
| 8-K · Current report | May 24, 2023 | Management or board change | SEC |
| 10-Q · Quarterly report | May 15, 2023 | Quarterly report | SEC |
| 8-K · Current report | May 15, 2023 | Results | SEC |
| 4 · Change in ownership | May 1, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 1, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Apr 24, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Apr 24, 2023 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Apr 5, 2023 | Big-stake notice | SEC |
| 10-K · Annual report | Mar 30, 2023 | Annual report | SEC |
| 8-K · Current report | Mar 30, 2023 | Results | SEC |
| 8-K · Current report | Mar 27, 2023 | Current report | SEC |
| 8-K · Current report | Jan 11, 2023 | Meeting outcome | SEC |
| 8-K · Current report | Jan 4, 2023 | Material contract | SEC |
| 4 · Change in ownership | Jan 4, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 4, 2023 | Insider trade | SEC |
| DEF 14A · Proxy statement | Dec 13, 2022 | Meeting notice | SEC |
| 10-Q · Quarterly report | Nov 14, 2022 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2022 | Results | SEC |
| 8-K · Current report | Oct 11, 2022 | Current report | SEC |
| 8-K · Current report | Sep 22, 2022 | Material contract | SEC |
| 10-Q · Quarterly report | Aug 15, 2022 | Quarterly report | SEC |
| 8-K · Current report | Aug 15, 2022 | Results | SEC |
| 10-Q · Quarterly report | May 16, 2022 | Quarterly report | SEC |
| 8-K · Current report | May 16, 2022 | Results | SEC |
| 4 · Change in ownership | Apr 8, 2022 | Insider trade | SEC |
| 10-K · Annual report | Mar 28, 2022 | Annual report | SEC |
| 8-K · Current report | Mar 28, 2022 | Results | SEC |
| 4 · Change in ownership | Mar 14, 2022 | Insider trade | SEC |
| SC 13G · Big-stake notice | Feb 14, 2022 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 4, 2022 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 3, 2022 | Insider trade | SEC |
| 8-K · Current report | Jan 28, 2022 | Results | SEC |
| 8-K · Current report | Dec 17, 2021 | Management or board change | SEC |
| 4 · Change in ownership | Dec 17, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Dec 17, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Dec 17, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Dec 17, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Dec 17, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2021 | Insider trade | SEC |
This page holds 200 of 952 filings. Open Filings
Cap table
Built by 6ix from Brainstorm Cell Therapeutics Inc.’s releases · as of Sep 30, 2026
- Common shares
- 11,034,775
- Fully diluted
- 11,034,775
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 11,034,775 | Sep 30, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 11,034,775 |
| Sep 30, 2026 | 14,259,377 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Jacob A Frenkel Other companies: BXP, Inc. (Director · Feb 24, 2010 – May 31, 2018 · Past); Loews Corporation (Director · Nov 30, 2009 – May 8, 2019 · Past); American International Group, Inc. New (Vice Chairman · Jul 1, 2007 – Sep 1, 2009 · Past) | Director · Since at least Mar 30, 2020 |
| Eyal Rubin Other companies: Nasus Pharma Ltd. (Executive Vice President and Chief Financial Officer · Since at least Nov 20, 2025); Protalix BioTherapeutics, Inc. (de) (Sr. VP and CFO · Sep 22, 2019 – Sep 23, 2024 · Past) | CFO and Treasurer · Nov 20, 2017 – Nov 20, 2017 · Past |
| Stacy R. Lindborg Other companies: Imunon, Inc. (President, Chief Executive Officer, and Board Director · Since at least Jun 4, 2021) | Director · Since at least Jun 1, 2020 |
| Alla Patlis | Interim Chief Financial Officer · Since at least May 13, 2015 |
| Alon Natanson | Chief Executive Officer · Feb 1, 2013 – Feb 1, 2013 · Past |
| Alon Pinkas | Director · Apr 19, 2013 – Jun 22, 2016 · Past |
| Anthony Polverino | Director · Since at least Jan 1, 2025 |
| Arturo Araya | Chief Commercial Officer · Feb 26, 2017 – Dec 24, 2019 · Past |
| Avi Israeli | Director · Apr 13, 2010 – Apr 13, 2014 · Past |
| Chaim Lebovits | President, Chief Executive Officer · Since at least Sep 28, 2015 |
All 25 people
| Person | Seat |
|---|---|
| Haro Hartounian | Executive Vice President, Chief Operating Officer · Since at least Nov 4, 2026 |
| Ibrahim B Dagher | Director · Since at least Apr 17, 2024 |
| Irit Arbel | Director · Since at least Jun 22, 2016 |
| Kirk Taylor | Chief Medical Officer · May 1, 2023 – May 1, 2023 · Past |
| Liat Sossover | Chief Financial Officer · Jun 23, 2010 – Dec 31, 2013 · Past |
| Mary Kay Turner | Senior Vice President, Patient Advocacy and Government Affairs · Since at least Nov 4, 2026 |
| Menghis Bairu | Director · Since at least Nov 4, 2026 |
| Menghisteab Bairu | Director · Since at least Feb 26, 2026 |
| Moshe Lion | Director · Jul 16, 2007 – Aug 31, 2009 · Past |
| Netta Blondheim-Shraga | Senior Vice President, Research and Development · Since at least Nov 4, 2026 |
| Nir Naor | Director · Since at least Nov 4, 2026 |
| Peter J. Pitts | Executive Chairman · Since at least Nov 4, 2026 |
| Sankesh Abbhi | Director · Mar 30, 2020 – Dec 10, 2021 · Past |
| Uri Yablonka | Director · Since at least Jun 6, 2014 |
| Yossef Levy | Vice President, Cell Production · Since at least Nov 4, 2026 |
Log in to ask 6ix AI your own questions about Brainstorm Cell Therapeutics Inc.